Stockreport

ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA® [Yahoo! Finance]

ImmunityBio, Inc.  (IBRX) 
PDF ImmunityBio's 400,000 square foot GMP fill-finish facility in Dunkirk, New York on track to be completed in 12-18 months with capacity to produce a million vials annual [Read more]